Video

Dr. Thierry Jahan on the CRS-207 Vaccine in Mesothelioma

​Thierry M. Jahan, MD, a clinical professor in the Department of Medicine at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib trial of CRS-207 in malignant pleural mesothelioma (MPM).

Thierry M. Jahan, MD, a clinical professor in the Department of Medicine at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses a phase Ib trial of CRS-207 in malignant pleural mesothelioma (MPM).

CRS-207 is a live-attenuated, double-deleted Listeria monocytogene engineered to express the tumor-associated antigen mesothelin. In the the phase Ib it was administered with chemotherapy to 38 patients with MPM. Of 34 evaluable patients, 59% (n = 20) had partial response posttreatment and 35% (n = 12) had stable disease, for an overall disease-control rate 94%.

There is a synergy between the exposure of the Listeria and the immunity that it triggers and the efficacy of the chemotherapy, said Jahan. The tumor-infiltrating lymphocytes (TILs) that are necessary to distribute the tumor are overexpressed and expanded through the vaccination, and this along with chemotherapy, is likely to improve the response rate, he said.

A global randomized trial is in the process of being implemented and should enroll its first patient sometime this year.

Related Videos
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for lorlatinib in ROS1-positive NSCLC after crizotinib and chemotherapy.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for taletrectinib in ROS1-positive advanced non–small cell lung cancer.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, on progression patterns and subsequent therapies after lorlatinib in ALK-positive NSCLC.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss preclinical CNS data for the ROS1 inhibitor zidesamtinib.
Gregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss data for zidesamtinib in ROS1-positive non–small cell lung cancer.
Yair Lotan, MD, UT Southwestern Medical Center
Alan Tan, MD, Vanderbilt-Ingram Cancer Center
Alex Herrera, MD
Roy S. Herbst, MD, PhD